Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boston ScientificBSX -2.50%77 EV-to-OCF is 18.44 as of Aug. 24, 2026, which is 55% below its 10-year median of 41.31. GuruFocus rates BSX with a GF Score™ of 77/100 and a GF Value™ of $106.99 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 850 Medical Devices & Instruments companies, Boston Scientific ranks worse than 73.18% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Boston Scientific's Enterprise Value is $83,499 Mil.
Boston Scientific's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $4,529 Mil. Therefore, Boston Scientific's EV-to-OCF for today is 18.44.
The historical rank and industry rank for Boston Scientific's EV-to-OCF or its related term are showing as below:
BSX'
s EV-to-OCF Range Over the Past 10 Years
Min: 17.06 Med: 41.31 Max: 207.14
Current: 18.44
During the past 13 years, the highest EV-to-OCF of Boston Scientific was 207.14. The lowest was 17.06. And the median was 41.31.
BSX's EV-to-OCF is ranked worse than 73.18% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 7.695
vs BSX: 18.44
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Boston Scientific (NYSE:BSX) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Boston Scientific's PE Ratio (TTM) for today is calculated as:
Boston Scientific's share price for today is $49.11.
Boston Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.470.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Boston Scientific EV-to-OCF Related Terms
Boston Scientific EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Boston Scientific's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Boston Scientific's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boston Scientific EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Boston Scientific's EV-to-OCF falls into.
Boston Scientific's current Enterprise Value is $83,499 Mil.
Boston Scientific's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,529 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boston Scientific (BSX) has a EV-to-OCF of 18.44 as of Aug. 24, 2026. This is 55% below median its historical median of 41.31. Over the past decade, Boston Scientific's EV-to-OCF has ranged from 17.06 to 207.14. According to the industry distribution chart, Boston Scientific ranks #622 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 73.2%.
Is Boston Scientific's EV-to-OCF too high?
Boston Scientific's current EV-to-OCF of 18.44 is 55% below median its 10-year median of 41.31. Over the past 10 years, this metric has ranged from a low of 17.06 to a high of 207.14. The Medical Devices & Instruments industry median EV-to-OCF is 7.70. Boston Scientific's value of 18.44 is 139.6% above this industry median. Based on the distribution chart, Boston Scientific ranks #622 out of 850 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Boston Scientific has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's EV-to-OCF compare to EW and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Boston Scientific ranks #622 out of 850 companies for EV-to-OCF. This places Boston Scientific in the lower half of its industry. The industry median EV-to-OCF is 7.70. Boston Scientific's value of 18.44 is 139.6% above this benchmark. Historically, Boston Scientific's own EV-to-OCF has ranged from 17.06 to 207.14 over the past decade. While the company's 10-year median is 41.31 vs. the industry median of 7.70, Boston Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.70, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boston Scientific's current EV-to-OCF of 18.44 is 139.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boston Scientific's current EV-to-OCF is 18.44, which is 55% below median its own 10-year median of 41.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is $106.99, compared to a current price of $49.11 — trading 54.1% below its estimated fair value. The current EV-to-OCF is 18.44, which is 55% below median its 10-year median of 41.31 and 139.6% above the Medical Devices & Instruments industry median of 7.70. Boston Scientific's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Boston Scientific (BSX), the current EV-to-OCF is 18.44 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of $49.11 is trading 54.1% below its estimated GF Value™ of $106.99.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for BSX:
EV-to-OCF: 18.44 (55% below median its 10-year median of 41.31)
GF Value™: $106.99 vs. price of $49.11 (54.1% below fair value)
Industry Position: 139.6% above the Medical Devices & Instruments median (#622 of 850)
No single metric tells the full story. See the BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
77GF Score
Get the complete analysis for BSX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSX has been successfully added to your 
